Community aquired pneumonia
Conditions
Interventions
Trade Name: Crestor
Pharmaceutical Form: Capsule*
Concentration unit: mg milligram(s)
Sponsors
Karolinska University Hospital Huddinge
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - age 55-85 years old - CAP diagnose - Written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - Previous participation in the study - pervious participation in any other clinical trial, within 6 months period - ongoing drug treatment with a statin or any other lipidlowering therapy - co-morbid condition with a life expectancy less than one year - serum ASAT or Serum ALAT>times UNL - serum creatinin kinase (s-CK) > 5 times UNL - serum kreatinin (S-Krea) > 200µkat/L -poorly controlledhypothyroid function - inhereditied myopathia - alcoholdependecy - drug treatment with erytromycin, proteas inhibitors, gemfibrozil, ciklosporin, niacin, fibrates (except fenofibrate) and ezetemib - any other condition after judgement of the investigator would make the patient unsuiteable for enrollment, or could interfere with the study protocol -preganacy or planned pregnancy or breastfeeding -
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine if treatment with rosuvastatin can reduce the rate of major cardiovascular events during 6 months in 55-85 years old patients who are hospitilazid for pneumonia.;Secondary Objective: - To determine if the rates of mortality and infectious disease events are correlated to rosuvastatin treatment or not - To determine if treatment with rosuvastatin has an effect on inflammatory parameters (IP) in plasma overe time. The IP parameters are HMGB1, PCT, high-sensitive CRP, IL-6 and other pro-inflammatory cytikines. - To investigate if changes in serum lipids and lipoprotein levels are correlated to major cardiovascular events and number and type of readmission, e.g. infectious or cancer - To determine if treatment with rosuvastatin has an effect on BNP levels in plasma over time - To investigate the prevalence of different airway pathogens in the study population - To investigate the clinical characteristics (demografi, confounders, co-morbidity and CRB-65 (pneumonia severity index) in the study population in relation to mortality ;Primary end point(s): proportion of patients readmissioned to hospital due to infectious diseases or cardiovascular events | — |
Countries
Sweden
Outcome results
None listed